logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

FLAT GLASS (06865) repurchased 140,000 A shares on October 27 for RMB2.2225 million.

date
16:06 27/10/2026
avatar
GMT Eight
FLAT GLASS (06865) announced that on October 27, 2026, it repurchased 140,000 A shares for RMB2.2225 million.
FLAT GLASS (06865) announced that on October 27, 2026, it repurchased 140,000 A shares for RMB2.2225 million.
Related Articles
HK Stock
WASION HOLDINGS (03393) repurchased 300,000 shares for HK$3.3 million on October 27.
HK Stock
Midea Group Co., Ltd (00300) repurchased 1.218 million A shares for RMB104 million on October 27.
HK Stock
LIVZON PHARMA (01513): The recombinant humanized anti-FXI bispecific antibody injection has been approved to conduct clinical trials for the indication of "prevention of venous thromboembolism after total knee arthroplasty"
WASION HOLDINGS (03393) repurchased 300,000 shares for HK$3.3 million on October 27.
HK Stock
Midea Group Co., Ltd (00300) repurchased 1.218 million A shares for RMB104 million on October 27.
HK Stock
LIVZON PHARMA (01513): The recombinant humanized anti-FXI bispecific antibody injection has been approved to conduct clinical trials for the indication of "prevention of venous thromboembolism after total knee arthroplasty"
HK Stock
RECOMMEND
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
icon
25/09/2026
From IT Services to Enterprise AI: What ATGL Must Prove Next
From IT Services to Enterprise AI: What ATGL Must Prove Next
icon
24/09/2026
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
icon
22/09/2026
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.